94 related articles for article (PubMed ID: 23320386)
1. Cost-benefit of the 21-gene breast cancer recurrence score assay for patients in Singapore.
de Lima Lopes G; Chien R; Hornberger J
Breast J; 2013; 19(2):220-1. PubMed ID: 23320386
[No Abstract] [Full Text] [Related]
2. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer breakthrough in gene profilings?
Bateman C
S Afr Med J; 2009 Nov; 99(11):780-2. PubMed ID: 20218471
[No Abstract] [Full Text] [Related]
4. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
5. Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?
Lamond NW; Skedgel C; Younis T
Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):243-50. PubMed ID: 23570435
[TBL] [Abstract][Full Text] [Related]
6. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
7. The financial burden of using Oncotype Dx for patients with lymph node-negative and estrogen receptor-positive breast cancer in Australia.
Sakata S; Cronk M
Asia Pac J Clin Oncol; 2014 Mar; 10(1):94-5. PubMed ID: 23718901
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer.
Vanderlaan BF; Broder MS; Chang EY; Oratz R; Bentley TG
Am J Manag Care; 2011; 17(7):455-64. PubMed ID: 21819166
[TBL] [Abstract][Full Text] [Related]
10. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.
Cosler LE; Lyman GH
Cancer Invest; 2009 Dec; 27(10):953-9. PubMed ID: 19909009
[No Abstract] [Full Text] [Related]
11. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
[TBL] [Abstract][Full Text] [Related]
13. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.
Retèl VP; Joore MA; Knauer M; Linn SC; Hauptmann M; Harten WH
Eur J Cancer; 2010 May; 46(8):1382-91. PubMed ID: 20359886
[TBL] [Abstract][Full Text] [Related]
15. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03).
Kondo M; Hoshi SL; Yamanaka T; Ishiguro H; Toi M
Breast Cancer Res Treat; 2011 Jun; 127(3):739-49. PubMed ID: 21082239
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
[TBL] [Abstract][Full Text] [Related]
20. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
Lyman GH; Cosler LE; Kuderer NM; Hornberger J
Cancer; 2007 Mar; 109(6):1011-8. PubMed ID: 17311307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]